Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 289

Results For "CENT"

4446 News Found

Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster
Drug Approval | November 11, 2022

Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster

The European Commission will review the CHMP recommendation and is expected to make a final decision soon.


Biogen appoints Christopher Viehbacher as President and CEO
People | November 11, 2022

Biogen appoints Christopher Viehbacher as President and CEO

Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies


Ayu Health receives US $27 million additional funding
News | November 11, 2022

Ayu Health receives US $27 million additional funding

The company is making its entry into the Hyderabad market through its unique asset-light business model


IMPCL registers impressive threefold increase in profit for FY21-22
News | November 11, 2022

IMPCL registers impressive threefold increase in profit for FY21-22

The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal


ASG Eye Hospitals enters Haryana and expands footprint in UP
Healthcare | November 10, 2022

ASG Eye Hospitals enters Haryana and expands footprint in UP

ASG is accelerating its doctor-led mission to enhance the quality of care, deliver eye care for all, and improve quality of life across India.


AGC to establish Life Science Company in 2023
News | November 10, 2022

AGC to establish Life Science Company in 2023

The Group will continue to make proactive investments of its management resources in the life science business


Lupin receives tentative approval from USFDA for Doxycycline Capsules
Drug Approval | November 09, 2022

Lupin receives tentative approval from USFDA for Doxycycline Capsules

Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US


Astec LifeSciences plan Capex of Rs. 300 - 350 Cr
News | November 08, 2022

Astec LifeSciences plan Capex of Rs. 300 - 350 Cr

R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab


Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
News | November 07, 2022

Balaxi Pharmaceuticals delivers strong growth in Q2 FY23

Revenue is up 23% whereas Profit After Tax expands 29% for the company